| Q1 2024 |
51 |
$455M |
+$76.9M |
-$77.5M |
-$609K |
OCUL, HROW, TGTX, KROS, RYTM, CPRX |
RESTATEMENT |
5/29/2024, 04:05 PM |
| Q4 2023 |
45 |
$372M |
+$63M |
-$56.4M |
+$6.61M |
HROW, TGTX, SLRN, RYTM, OCUL, CPRX |
13F-HR |
2/14/2024, 04:05 PM |
| Q3 2023 |
53 |
$304M |
+$47.9M |
-$88.3M |
-$40.4M |
HROW, SLRN, OCUL, TGTX, RYTM, CPRX |
13F-HR |
11/14/2023, 08:04 PM |
| Q2 2023 |
50 |
$415M |
+$135M |
-$34.6M |
+$100M |
SLRN, HROW, OCUL, TELA, CRNX, KROS |
13F-HR |
8/14/2023, 06:11 PM |
| Q1 2023 |
41 |
$334M |
+$42.1M |
-$6.65M |
+$35.5M |
HROW, OCUL, TELA, RYTM, CRNX, KPTI |
13F-HR |
5/12/2023, 06:49 PM |
| Q4 2022 |
40 |
$288M |
+$59.8M |
-$21.8M |
+$38M |
HROW, TELA, RYTM, OCUL, CRNX, CYTK |
13F-HR |
2/10/2023, 03:05 PM |
| Q3 2022 |
42 |
$242M |
+$30.5M |
-$14.3M |
+$16.2M |
HROW, OCUL, RYTM, TELA, CRNX, CYTK |
13F-HR |
11/14/2022, 03:20 PM |
| Q2 2022 |
47 |
$222M |
+$35.6M |
-$30.8M |
+$4.78M |
HROW, OCUL, CDXS, CRNX, CYTK, TELA |
13F-HR |
8/15/2022, 04:03 PM |
| Q1 2022 |
44 |
$316M |
+$33.3M |
-$47.8M |
-$14.5M |
OCUL, CDXS, CMRX, HROW, CRNX, CYTK |
13F-HR |
5/16/2022, 04:05 PM |
| Q4 2021 |
37 |
$466M |
+$50.2M |
-$30.8M |
+$19.4M |
CDXS, OCUL, CMRX, CLDX, HROW, CYTK |
13F-HR |
2/14/2022, 03:05 PM |
| Q3 2021 |
48 |
$535M |
+$61M |
-$12.9M |
+$48M |
OCUL, CLDX, CDXS, CMRX, HROW, SMLR |
13F-HR |
11/15/2021, 06:17 PM |
| Q2 2021 |
47 |
$569M |
+$44.9M |
-$19.8M |
+$25.1M |
OCUL, CMRX, CLDX, BBIO, CDXS, HROW |
13F-HR |
8/16/2021, 05:13 PM |
| Q1 2021 |
54 |
$654M |
+$140M |
-$37.3M |
+$102M |
OCUL, CMRX, TARA, BBIO, CDXS, ETON |
13F-HR |
5/17/2021, 07:03 PM |
| Q4 2020 |
57 |
$748M |
+$84.4M |
-$20M |
+$64.4M |
OCUL, TARA, EIDX, ETON, CDXS, CRDF |
13F-HR |
2/12/2021, 04:15 PM |
| Q3 2020 |
49 |
$479M |
+$114M |
-$23.6M |
+$90.5M |
OCUL, TARA, ETON, CRDF, AFIB, CCXI |
13F-HR |
11/16/2020, 03:30 PM |
| Q2 2020 |
47 |
$487M |
+$183M |
-$21.2M |
+$162M |
TARA, OCUL, NLTX, CCXI, ETON, CDXS |
13F-HR |
8/14/2020, 04:47 PM |
| Q1 2020 |
44 |
$377M |
+$103M |
-$31.8M |
+$71.6M |
TARA, FTSV, OCUL, NLTX, CDXS, EIDX |
13F-HR |
5/15/2020, 04:30 PM |
| Q4 2019 |
47 |
$510M |
+$106M |
-$2.84M |
+$104M |
EPZM, CDXS, FTSV, STXS, TPTX, OCUL |
13F-HR |
2/14/2020, 03:30 PM |
| Q3 2019 |
49 |
$269M |
+$67.5M |
-$20.1M |
+$47.4M |
CDXS, STXS, EPZM, IMMY, EIDX, TPTX |
13F-HR |
11/14/2019, 03:30 PM |
| Q2 2019 |
43 |
$318M |
+$63.5M |
-$15.9M |
+$47.6M |
CDXS, IMMY, AXGN, EPZM, QURE, ODTC |
13F-HR |
8/14/2019, 04:30 PM |
| Q1 2019 |
53 |
$354M |
+$127M |
-$50.9M |
+$76.2M |
CDXS, AXGN, EPZM, CERC, AMRN, QURE |
13F-HR |
5/15/2019, 04:30 PM |
| Q4 2018 |
46 |
$268M |
+$47.4M |
-$19.3M |
+$28.2M |
CDXS, AXGN, LOXO, AMRN, BPMC, IMMY |
13F-HR |
2/14/2019, 04:00 PM |
| Q3 2018 |
46 |
$393M |
+$45M |
-$41.6M |
+$3.35M |
AXGN, CDXS, LOXO, AMRN, BPMC, DCPH |
13F-HR |
11/14/2018, 03:30 PM |
| Q2 2018 |
35 |
$383M |
+$94.3M |
-$33.1M |
+$61.2M |
AXGN, LOXO, CDXS, FGEN, BPMC, PTE |
13F-HR |
8/14/2018, 04:31 PM |
| Q1 2018 |
37 |
$329M |
+$54.6M |
-$23.7M |
+$30.8M |
AXGN, BPMC, LOXO, CDXS, FGEN, SBBP |
13F-HR |
5/14/2018, 05:00 PM |
| Q4 2017 |
35 |
$302M |
+$53.2M |
-$5.22M |
+$48M |
AXGN, BPMC, FGEN, LOXO, IMMU, CDXS |
13F-HR |
2/9/2018, 03:30 PM |
| Q3 2017 |
32 |
$281M |
+$36.5M |
-$12.3M |
+$24.2M |
BPMC, AXGN, FGEN, IMMU, LOXO, CDXS |
13F-HR |
11/14/2017, 03:17 PM |
| Q2 2017 |
41 |
$238M |
+$36.2M |
-$2.69M |
+$33.5M |
BPMC, AXGN, FGEN, LOXO, SBBP, CDXS |
13F-HR |
8/14/2017, 04:34 PM |
| Q1 2017 |
43 |
$198M |
+$40.9M |
-$8.45M |
+$32.4M |
BPMC, AXGN, FGEN, NVLNF, CMRX, AGIO |
13F-HR |
5/15/2017, 06:15 AM |
| Q4 2016 |
39 |
$168M |
+$44.5M |
-$10.3M |
+$34.2M |
BPMC, AXGN, ARIA, GNMX, FGEN, FOMX |
13F-HR |
2/21/2017, 03:27 PM |
| Q3 2016 |
43 |
$185M |
+$33M |
-$22.4M |
+$10.5M |
BPMC, AXGN, ARIA, MDGN, AGIO, FGEN |
13F-HR |
11/14/2016, 11:30 AM |
| Q2 2016 |
49 |
$144M |
+$30.6M |
-$8.99M |
+$21.7M |
AXGN, MDGN, ARIA, FGEN, BPMC, IMMY |
RESTATEMENT |
8/12/2016, 04:35 PM |
| Q1 2016 |
50 |
$147M |
+$32.7M |
-$14M |
+$18.7M |
AXGN, ARIA, RARE, FGEN, MDGN, CARA |
RESTATEMENT |
5/27/2016, 03:29 PM |
| Q4 2015 |
51 |
$231M |
+$45.5M |
-$18.1M |
+$27.4M |
RARE, AXGN, FGEN, GERN, MDGN, IMMY |
13F-HR |
2/12/2016, 11:57 AM |
| Q3 2015 |
47 |
$199M |
+$31.8M |
-$24.1M |
+$7.78M |
CMRX, RARE, CEMP, AXGN, MDGN, AMAG |
13F-HR |
11/13/2015, 09:44 AM |
| Q2 2015 |
43 |
$243M |
+$41.6M |
-$20.9M |
+$20.7M |
CMRX, CEMP, RTRX, AMAG, ARIA, RARE |
13F-HR |
8/14/2015, 10:27 AM |
| Q1 2015 |
37 |
$215M |
+$50.1M |
-$24.7M |
+$25.4M |
CMRX, CEMP, ARIA, RTRX, CLVSQ, AMAG |
13F-HR |
5/15/2015, 11:41 AM |
| Q4 2014 |
36 |
$198M |
+$53.6M |
-$4.72M |
+$48.9M |
CMRX, AGIO, CEMP, RTRX, ARIA, PCYC |
13F-HR |
2/13/2015, 06:06 AM |
| Q3 2014 |
28 |
$128M |
+$25.7M |
-$7.77M |
+$18M |
CMRX, PCYC, RTRX, ARIA, AGIO, CLVSQ |
13F-HR |
11/14/2014, 09:27 AM |
| Q2 2014 |
27 |
$116M |
+$30.2M |
-$3.59M |
+$26.6M |
CMRX, RTRX, ARIA, PCYC, GNMK, BINDQXXXX |
13F-HR |
8/14/2014, 10:19 AM |
| Q1 2014 |
30 |
$135M |
+$63.5M |
-$13.5M |
+$50M |
RTRX, ARIA, CMRX, PCYC, NSPR, OMER |
13F-HR |
5/15/2014, 10:48 AM |
| Q4 2013 |
21 |
$122M |
|
|
|
GENTY, GERN, PCYC, ARIA, P103PS, OMER |
13F-HR |
2/13/2014, 06:29 PM |